Core Viewpoint - Health Road (02587.HK) announced the sale of a 51% stake in its subsidiary, Fujian Jianchen Pharmaceutical Co., Ltd., to Ms. Xiao Jing for a total consideration of RMB 1.6779 million, effective December 24, 2025. Following the sale, the subsidiary will no longer be part of the company's consolidated financial statements [1]. Group 1 - The sale is driven by the temporary revenue increase from stockpiling Oseltamivir during the flu outbreak at the end of 2023, which highlighted the limitations of the subsidiary as a single-product pharmaceutical wholesaler [1]. - Since August 2024, the subsidiary's performance has declined significantly due to unmet expectations from drug procurement agreements with other pharmaceutical companies, leading to a substantial drop in revenue and net profit [1]. - The company aims to use the proceeds from the sale to develop its enterprise services and digital marketing services, focusing on cost reduction and efficiency improvement [1].
健康之路(02587.HK)拟167.79万元出售福建健宸医药51%股权